|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
|
|
Dietary interventions for multiple sclerosisFarinotti M, Simi S, Di Pietrantonj C, McDowell N, Brait L, Lupo D, Filippini G SummaryDietary interventions as complementary therapies for MSBecause available conventional treatments are only partially effective and may produce side effects, most patients with MS use therapies proposed by complementary and alternative medicine - usually diets and dietary supplements. In fact, an Internet search using the terms "multiple sclerosis" and "diet" produces over 6 million references, indicating that these treatments are widely used and believed in by the MS consumer community. The most common dietary interventions are supplementation with polyunsaturated fatty acids, allergen (gluten and milk)-free diets, vitamins, and micronutrients and antioxidants such as selenium, Gingko biloba extracts, coenzyme Q10.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
January 24. 2007 AbstractBackgroundClinical and experimental data suggest that certain dietary regimens, particularly those including polyunsaturated fatty acids (PUFAs) and vitamins might improve outcomes in people with multiple sclerosis (MS). Diets and dietary supplements are much used by people with MS in the belief that they might improve disease outcomes. ObjectivesTo answer MS consumers' questions regarding the efficacy and safety of dietary regimens for MS. Search strategyWe searched the Cochrane MS Group trial register (February 2006), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Library, Issue 1, 2006, MEDLINE (PubMed) (1966 to March 2006), EMBASE (1974 to March 2006) and the bibliographies of papers found. Selection criteriaAll randomised controlled trials comparing a specific dietary intervention, diet plan or dietary supplementation, with no dietary modification or placebo, were eligible. Data collection and analysisTwo reviewers independently selected articles, assessed trial quality and extracted data. Main resultsTrial quality was poor, particularly as regards descriptions of randomisation, blinding and adverse event reporting. Some studies had large numbers of drop-outs; dropouts were never included in the analyses. PUFAs did not have a significant effect on disease progression, measured as worsening of Disability Status Scale. Omega-6 fatty acids (11-23 g/day linoleic acid) had no benefit in 75 relapsing remitting (RR) MS patients (progression at two years: relative risk (RR)=0.78, 95% CI [0.45 to 1.36]) or in 69 chronic progressive (CP) MS patients (RR=1.67, 95% CI [0.75 to 3.72]. Linoleic acid (2.9-3.4 g/day) had no benefit in CPMS (progression at two years: RR=0.78, 95% CI [0.43 to 1.42]). Slight decreases in relapse rate and relapse severity were associated with omega-6 fatty acids in some small studies, however these findings are limited by the limited validity of the endpoints. Authors' conclusionsPUFAs seem to have no major effect on the main clinical outcome in MS (disease progression), and does not substantially affect the risk of clinical relapses over 2 years. However, the data available are insufficient to assess any potential benefit or harm from PUFA supplementation. Evidence bearing on the possible benefits and risks of vitamin supplementation and antioxidant supplements in MS is lacking. More research is required to assess the effectiveness of diets interventions in MS. |